@evelobio.com
View Evelo’s SEC filings Direct all inquiries to [email protected]
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
About
Description
Evelo Biosciences is a clinical-stage biotechnology company that specializes in developing SINTAX™ medicines, a new class of orally delivered treatments for inflammatory disease. They have recently announced positive Phase 2 clinical data for their investigational oral biologic, EDP1815, in the treatment of psoriasis. This data marks a significant advancement in the field, demonstrating the ability to harness the Small Intestinal Axis to make a clinical impact.
EDP1815 has shown clinically and statistically significant improvement in the Psoriasis Area and Severity Index (PASI) score, with comparable safety and tolerability data to placebo. Evelo Biosciences aims to address the unmet needs of millions of patients living with inflammatory diseases through their innovative and affordable treatment options. With ongoing clinical programs in psoriasis, atopic dermatitis, and COVID-19, Evelo is committed to transforming healthcare by developing effective, safe, and accessible medicines
Company Type
Public Company
Company Size
51-200
Year Founded
2015
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online